POINT Biopharma Global released new preclinical data from the Company’s pan-cancer fibroblast activation protein-alpha targeted program, PNT2004. The preclinical study focused on assessing the potential of the lead candidate in the PNT2004 clinical program, 177Lu-PNT6555, in combination with anti-PD-1 immunotherapy. The CT26-mFAP tumor model used expresses low levels of FAP, grows aggressively, and is insensitive to anti-PD-1 immunotherapy. The study found that combination treatment with 177Lu-PNT6555 and anti-PD-1 resulted in a significant survival benefit, as compared to either treatment independently. "While the initial clinical development of 177Lu-PNT6555 has focused on its application as a monotherapy, we have always held optimism for its broad potential in combination therapies." said Joe McCann, Ph.D., Chief Executive Officer of POINT Biopharma. "Radioligand therapy could offer a synergistic mechanism of action with multiple existing therapeutic classes, expanding their applicability or effectiveness. For example, RLT combined with checkpoint blockade could unleash an immune attack against tumors that are otherwise insensitive to immunotherapy, or RLT combined with DNA repair/cell cycle inhibitors could amplify DNA damage to increase cell death. As a pan-cancer program, the 177Lu-PNT6555 lead presents significant opportunities for both monotherapy and combination trials in a variety of indications of high unmet need. We look forward to providing more data in the coming months on both our FAP program as well as our other exciting next generation radioligand programs."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PNT:
- POINT Biopharma Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with Immunotherapy
- Point Biopharma price target lowered to $14 from $17 at Piper Sandler
- Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003
- POINT Biopharma Publishes Preclinical Data for Actinium-Labelled PNT2001, a Next-Generation PSMA Ligand, at EANM’s Annual Congress